The concept of allostasis and allostatic load: Psychoneuroimmunological findings;Das stresskonzept von allostase und allostatic load: Einordnung psychoneuroimmunologischer forschungsbefunde an beispielen zur autoimmunität und onkologie

PPmP Psychotherapie Psychosomatik Medizinische Psychologie

Volumn 55, Issue 11, 2005, Pages 452-461

  Schulz, Karl Heinz ^a,c   Heesen, Christoph ^b   Gold, Stefan M ^d  

^a Institut und Poliklinik für Medizinische Psychologie   (Germany)

^b Neurologische Poliklinik   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Multiple sclerosis; Oncology; Psychoneuroimmunology; Stress

Indexed keywords

CATECHOLAMINE; CORTICOTROPIN; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ALLOSTASIS; ALLOSTATIC LOAD; ARTICLE; BREAST CANCER; CONCEPT FORMATION; DISEASE PREDISPOSITION; HUMAN; MULTIPLE SCLEROSIS; NONLINEAR SYSTEM; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOLOGICAL THEORY; PSYCHOPHYSIOLOGY; REPETITIVE STRAIN INJURY; STRESS;

ADAPTATION, PHYSIOLOGICAL; BREAST NEOPLASMS; HOMEOSTASIS; HUMANS; MULTIPLE SCLEROSIS; STRESS, PSYCHOLOGICAL; TERMINOLOGY;

EID: 28244454590     PISSN: 09372032     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-866939     Document Type: Article

References (85)

1. Cannon WB. Emotional stimulation of adrenal secretion. Am J Physiol 1911; 28: 64-70
2. Cannon WB. The emergency function of the adrenal medulla in pain and major emotions. Am J Physiol 1914; 33: 356-372
3. Selye H. A syndrome produced by diverse noxious agents. Nature 1936; 138: 32
4. Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol 1946; 6: 117-230
5. Mason JW. A re-evaluation of the concept of "non-specificity" in stress theory. J Psychiatr Res 1971; 8: 323-333
6. Dimsdale JE, Moss J. Plasma catecholamines in stress and exercise. JAMA 1980; 243: 340-342
7. Chrousos GP, Gold PW. The concept of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992; 267: 1244-1252
8. Chrousos GP. Syndromes of glucocorticoid resistance. Ann Int Med 1993; 119: 1113-1124
9. Besedovsky HO, Sorkin E. Network of immune-endocrine interactions. Clin Exp Immunol 1977; 27: 1-12
10. Ader R, Felten DL, Cohen N (eds). Psychoneuroimmunology. San Diego: Academic Press, 2001
11. Sterling P, Eyer J. Allostasis: A new paradigm to explain arousal pathology. In: Fisher S, Reason J (eds): Handbook of life stress, cognition and health. New York: Wiley, 1988: 629-649
12. McEwen BS. Protection and damage from acute and chronic stress. Allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Ann N Y Acad Sci 2004; 1032: 1-7
13. Schulkin J. Corticotropin-releasing hormone signals adversity in both the placenta and the brain: regulation by glucocorticoids and allostatic overload. J Endocrinol 1999; 161: 349-356
14. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med 1998; 338: 171-179
15. Koob GF, LeMoal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24: 97-129
16. McEwen BS, Seeman T. Protective and damaging effects of mediators of stress. Elaborating and testing the concepts of allostasis and allostatic load. Ann NY Acad Sci 1999; 896: 30-47
17. McEwen BS, Wingfield JC. The concept of allostasis in biology and bio-medicine. Hormones and Behavior 2003; 43: 2-15
18. McEwen BS, Wingfield JC. Response to commentaries on the concept of allostasis. Hormones and Behavior 2003; 43: 28-30
19. Kaplan JR, Petterson K, Manuck SB, Olsson G. Role of sympatho-adrenal medullary activation in the initiation and progression of atheriosclerosis. Circulation 1991; 84, Suppl VI: VI23-VI32
20. Lupien SJ, McEwen BS. The acute effects of corticosteroids on cognition: Integration of animal and human model studies. Brain Res Rev 1997; 24: 1-27
21. Haddad JJ, Saade NE, Safieh-Garabedian B. Cytokines and neuro-immune-endocrine interactions: A role for the hypothalamic-pituitary- adrenal revolving axis. J Neuroimmunol 2002; 133: 1-19
22. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000; 21: 55-89
23. Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Ann Rev Immunol 2002; 20: 125-163
24. McEwen BS, Biron CA, Brunson K et al. Neural-endocrine-immune interactions: The role of adrenocorticoids as modulators of immune function in health and disease. Brain Res Rev 1997; 23: 79-133
25. McEwen BS. Interacting mediators of allostasis and allostatic load: towards an understanding of resilience in aging. Metabolism 2003; 52 (Suppl 2): 10-16
26. Seeman T, McEwen B, Rowe J, Singer BH. Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proc Natl Acad Sci U S A 2001; 98: 4770-4775
27. Yamada K, Duong DT, Scott DK et al. CCAAT/Enhancer-binding protein is an accessory factor for the glucocorticoid response from the cAMP response element in the rat phosphoenolpyruvate carboxykinase gene promoter. J Biol Chem 1999; 274: 5880-5887
28. McEwen BS. Plasticity of the hippocampus: Adaptation to chronic stress and allostatic load. Ann NY Acad Sci 2001; 933: 265-277
29. Cohen S, Hamrick N, Rodriguez MS et al. Reactivity and vulnerability to stress-associated risk for upper respiratory illness. Psychosom Med 2002; 64: 302-310
30. Wilder RL. Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol 1995; 13: 307-338
31. Schorr EC, Arnason BG. Interactions between the sympathetic nervous system and the immune system. Brain Behav Immun 1999; 13: 271-278
32. Sternberg EM, Glowa JR, Smith MA et al. Corticotropin releasing hormone related behavioural and neuroendocrine response to stress in Lewis and Fischer rats. Brain Res 1992; 570: 54-60
33. Mason D, MacPhee I, Antoni F. The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat. Immunol 1990; 70: 1-5
34. Kuroda Y, Mori T, Hori T. Restraint stress suppresses experimental allergic encephalomyelitis in Lewis rats. Brain Res Bull 1994; 34: 15-17
35. Bartolomucci A, Sacerdote P, Panerai AE et al. Chronic psychosocial stress-induced down-regulation of immunity depends upon individual factors. J-Neuroimmunol 2003; 141 (1-2): 58-64
36. MacPhee I, Antoni FA, Mason DW. Spontaneous recovery from rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. J Exp Med 1989; 169: 431-445
37. Bolton C, Flower RJ. The effect of anti-glukokortikoid RU 38 486 on steroid-mediated suppression of experimental allergic encephalomyelitis (EAE) in the Lewis rat. Life Sci 1989; 45: 97-104
38. Michelson D, Stone L, Galliven E et al. Multiple sclerosis is accociated with alterations in hypothalamic-pituitary-axis function. J Clin Endocrinol Metab 1994; 79: 848-853
39. Grasser A, Möller A, Backmund A et al. Heterogeneity of hypothalamic-pituitary-adrenal system response to a combined dexamethasone-CRH test in multiple sclerosis. Exp Clin Endocrinol Diabetes 1996; 104: 31-37
40. Wei T, Lightman SL. The neuroendocrine axis in patients with multiple sclerosis. Brain 1997; 120: 1067-1076
41. Purba JS, Raadsheer F, Hofman MA et al. Increased number of corticotropin releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of patients with multiple sclerosis. Neuroendocrinol 1995; 62: 62-70
42. Reder AT, Lowy MT, Meltzer HY, Antel JP. Dexamethasone suppression test abnormalities in multiple sclerosis: relation to ACTH therapy. Neurology 1987; 37: 849-853
43. Limone P, Ferrero B, Calvelli P et al. Hypothalamo-pituitary-adrenal axis function and cytokine production in multiple sclerosis with or without interferon-β treatment. Acta Neurol Scand 2002; 105: 372-377
44. Then Bergh F, Kümpfel T, Trenkwalder C et al. Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology 1999; 53: 772-777
45. Heesen C, Gold SM, Raji A et al. Cognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosis. Psychoneuroendocrinol 2002; 27: 505-517
46. Schumann EM, Kümpfel T, Then Bergh F et al. Activity of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: correlations with gadolinium-enhancing lesions and ventricular volume. Ann Neurol 2002; 51: 763-767
47. Frohman EM, Monson NL, Lovett-Racke AE, Racke MK. Autonomic regulation of neuroimmunological responses: implications for multiple sclerosis. J Clin Immunol 2001 ; 21: 61-73
48. Cosentino M, Zaffaroni M, Marino F et al. Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J Neuroimmunol 2002; 133 (1-2): 233-240
49. Flachenecker P, Reiners KH, Krauser M et al. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler 2001; 7: 324-327
50. Huitinga I, Erkut ZA, Beurden D Van, Swaab DF. The hypothalamo-pituitary- adrenal axis in multiple sclerosis. Ann NY Acad Sci 2003; 992: 118-128
51. Then Bergh F, Grasser A, Trenkwalder C et al. Binding characteristics of the glucocorticoid receptor in peripheral blood lymphocytes in multiple sclerosis. J Neurol 1999; 246: 292-298
52. Correale J, Gilmore W, Li S et al. Resistance to glucocorticoid-induced apoptosis in PLP peptide-specific T cell clones from patients with progressive MS. J Neuroimmunol 2000; 109: 197-210
53. Winsen L van, Muris D, Dijkstra C, Polman C. Glucocorticoid sensitivity in patients with multiple sclerosis. Mult Scler ECTRIMS, 2002, Poster P274
54. DeRijk RH, Eskandari F, Sternberg EM. Corticosteroid resistance in a subpopulation of multiple sclerosis patients as measured by ex vivo dexamethasone inhibition of LPS induced IL-6 production. J Neuroimmunol 2004; 151 (1-2): 180-188
55. Karaszewski JW, Reder AT, Maselli R et al. Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol 1990; 27: 366-372
56. Zoukos Y, Kidd D, Woodroofe MN et al. Increased expression of high affinity IL-2 receptors and beta-adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis. Brain 1994; 117 (Pt 2): 307-315
57. Zoukos Y, Thomaides TN, Kidd D et al. Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study. J Neurol Neurosurg Psychiatry 2003; 74: 197-202
58. Heesen C, Gold SM, Sondermann J et al. Oral terbutaline differentially affects cytokine (IL-10, IL-12, TNF, IFNγ) release in multiple sclerosis patients and controls. J Neuroimmunol 2002; 132: 189-195
59. Giorelli M, Livrea P, Trojano M. Post-receptorial mechanisms underlie functional disregulation of beta2-adrenergic receptors in lymphocytes from Multiple Sclerosis patients. J Neuroimmunol 2004; 155: 143-149
60. Frohman EM, Vayuvegula B, Noort S van den, Gupta S. Norepinephrine inhibits gamma-interferon-induced MHC class II (Ia) antigen expression on cultured brain astrocytes. J Neuroimmunol 1988; 17: 89-101
61. Keyser J De, Wilczak N, Leta R, Streetland C. Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology 1999; 53: 1628-1633
62. Heesen C, Gold SM, Hartmann S et al. Endocrine and cytokine response to standardized physical stress in patients with multiple sclerosis and healthy controls. Brain Behav Immun 2003; 17: 473-481
63. Heesen C, Köhler G, Gross R et al. Fatigue in multiple sclerosis: altered cardiovascular and cytokine responses to cognitive stress. Mult Scler 2005; 11: 51-57
64. Heesen C, Schulz H, Schmidt M et al. Endocrine and cytokine response to acute psychological stress in multiple sclerosis. Brain Behav Immun 2002; 16: 282-287
65. Ackerman KD, Martino M, Heyman R et al. Stressor-induced alteration of cytokine production in multiple sclerosis patients and controls. Psychosom Med 1998; 60: 484-491
66. Fassbender K, Schmidt R, Mossner R et al. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch Neurol 1998; 55: 66-72
67. Keyser J De, Zeinstra E, Wilczak N. Astrocytic beta2-adrenergic receptors and multiple sclerosis. Neurobiol Dis 2004; 15: 331-339
68. Keyser J De, Zeinstra E, Mostert J, Wilczak N. Beta 2-adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis. Trends Pharmacol Sci 2004; 25: 67-71
69. Kümpfel T, Then Bergh F, Friess E et al. Dehydroepiandrosterone response to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing hormone test in patients with multiple sclerosis. Neuroendocrinology 1999; 70: 431-438
70. Huitinga I, Erkut ZA, Beurden D van, Swaab DF. Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions. Ann Neurol 2004; 55: 37-45
71. Gold SM, Raji A, Huitinga I et al. Hypothalamo-pituitary-adrenal axis hyperactivity predicts disease progression in multiple sclerosis, (zur Publikation eingereicht)
72. Pharoah PDP, Day NE, Duffy S et al. Family history and the risk of breast cancer: A systemic review and meta-analysis. Int J Cancer 1997; 71: 800-809
73. Arver B, Du Q, Chen J et al. Hereditary breast cancer: A review. Cancer Biol 2000; 10: 271-288
74. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast cancer and ovarian cancer. Cancer 1996; 77: 2318-2324
75. Bovbjerg DH, Valdimarsdottir HB. Interventions for healthy individuals at familial risk for cancer. In: Baum A, Anderson BL (eds): Psychosocial interventions for cancer. Washington: American Psychological Association, 2001: 305-320
76. Cohen M, Klein E, Kuten A et al. Increased emotional distress in daughters of breast cancer patients is associated with decreased natural killer cytotoxic activity, elevated levels of stress hormones and decreased secretion of TH1 cytokines. Int J Cancer 2002; 100: 347-354
77. Gold SM, Zakowski SG, Valdimarsdottir HB, Bovbjerg DH. Stronger endocrine responses after brief psychological stress in women at familial risk of breast cancer. Psychoneuroendocrinology 2003; 28: 584-593
78. Kirschbaum C, Pirke KM, Hellhammer DK. The "Trier Social Stress Test" -a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 1993; 28: 76-81
79. James GD, Berge-Landry H van, Valdimarsdottir HB et al. Urinary catecholamine levels in daily life are elevated in women at familial risk of breast cancer. Psychoneuroendocrinology 2004; 29: 831-838
80. Dettenborn L, James GD, Berge-Landry H van et al. Heightened cortisol responses to daily stress in working women at familial risk for breast cancer. Biological Psychology, (in press)
81. Valdimarsdottir HB, Zakowski SG, Gerin W et al. Heightened psychobiological reactivity to laboratory stressors in healthy women at familial risk of breast cancer. J Behav Med 2002; 25: 51-65
82. Bovbjerg DH, Valdimarsdottir HB. Familial cancer, emotional distress, and low natural cytotoxic activity in healthy women. Ann Oncol 1993; 4: 745-752
83. Imai K, Matsuyama S, Miyake S et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356: 1795-1799
84. Gold SM. Acute endocrine stress reactivity and recovery in women at familial risk of breast cancer. Dissertation. Universität Hamburg: 2003, erhältlich unter http://www.sub.uni-hamburg.de/opus/volltex te/2003/1023/
85. Dallman MF. Stress by any other name. Horm Behav 2003; 43: 18-20